TNF Alpha Inhibitors Market Definition And Segments
TNF alpha inhibitors refer to medications that are used to treat inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis, and juvenile idiopathic arthritis and that help to reduce or eliminate inflammation. TNF inhibitors may increase the risk of skin cancer, particularly non-melanoma skin cancers like squamous cell carcinoma.
The main types of drugs in TNF alpha inhibitors market are remicade (infliximab), enbrel (etanercept), humira (adalimumab), cimzia (certolizumab pegol), and simponi (golimumab). Remicade is a prescription medication for people with moderately to severely active Crohn's disease who haven't responded to other treatments. The different routes of administration include oral, subcutaneous, intravenous, and others and involve various types of diseases such as inflammatory bowel disease, psoriatic arthritis, ulcerative colitis (UC), rheumatoid arthritis, ankylosing spondylitis, and others.
The TNF alpha inhibitors market covered in this report is segmented –
1) By Drug: Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), Simponi (Golimumab)
2) By Route Of Administration: Oral, Subcutaneous, Intravenous, Other Route Of Administration
3) By Disease Type: Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis (UC), Rheumatoid Arthritis, Ankylosing Spondylitis, Other Disease Types
The TNF alpha inhibitors market size has grown marginally in recent years. It will grow from $43.09 billion in 2023 to $43.57 billion in 2024 at a compound annual growth rate (CAGR) of 1.1%. The growth in the historic period can be attributed to healthcare system integration, physician adoption and prescriptions, patient demand and awareness, advancements in biotechnology, expanded indications.
The TNF alpha inhibitors market size is expected to see steady growth in the next few years. It will grow to $47.54 billion in 2028 at a compound annual growth rate (CAGR) of 2.2%. The growth in the forecast period can be attributed to precision drug delivery, patient-centric focus, immunotherapy evolution, market expansion strategies, personalized medicine approach. Major trends in the forecast period include real-world evidence utilization, adoption of combination therapies, market entry strategies, expanded therapeutic applications, biosimilars competition.
The Prevalence Of Inflammatory Diseases Driving Tnf Alpha Inhibitor Market Growth
The growing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis is a key factor driving the growth of the TNF alpha inhibitor market. Tumor necrosis factor-alpha (TNF alpha) inhibitors are commonly used in gastroenterology, dermatology, and rheumatology for the treatment of various immune-mediated inflammatory diseases. Globally, the prevalence of inflammatory bowel disease (IBD) is about 0.5-24.5 cases of ulcerative colitis per 100,000 person-years and 0.1-16 cases of Crohn's disease per 100,000 person-years, and overall, the IBD prevalence is 396 cases per 100,000 people each year. Thus, the increasing number of cases of inflammatory diseases increases the demand for TNF alpha inhibitors, contributing to the growth of the TNF alpha inhibitors market.
Rising Geriatric Population Boosting Tnf Alpha Inhibitors Market
An increasing geriatric population is expected to propel the growth of the Tnf alpha inhibitors market going forward. The geriatric population, or elderly population, refers to people who are 65 years old or older. Ageing is more susceptible to autoimmune disorders and associated with increased inflammatory activity in the blood, and TNF-alpha inhibitors have been shown to be effective in reducing inflammation and atherosclerosis in the geriatric population. For instance, in October 2021, according to the World Health Organization, a Switzerland-based specialized agency, there will be 1.4 billion people over the age of 60, up from 1 billion in 2020. The number of individuals in the world who are 60 or older will double (to 2.1 billion) by 2050. Between 2020 and 2050, the number of people 80 or older is projected to treble, reaching 426 million. Therefore, the increasing geriatric population is driving the growth of the Tnf alpha inhibitors market.
Major companies operating in the tnf alpha inhibitors market report are HanAll Biopharma Co.Ltd., Pfizer Inc., Johnson & Johnson, Janssen Biotech lnc., Merck & co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Amgen Inc., Celgene Corporation, LEO Pharma A/S, Biogen Inc., Sandoz International GmbH, Cadila Healthcare Limited, Bionovis SA, UCB S.A, Intas Pharmaceuticals Ltd., Samsung Bioepis Co.Ltd., Celltrion Healthcare Co. Ltd., LG Life Sciences Ltd., MedImmune LLC, AryoGen Pharmed Co.Ltd., Ablynx NV, Reliance Life Sciences Pvt. Ltd., CASI Pharmaceuticals Inc., Momenta Pharmaceuticals lnc., EPIRUS Biopharmaceuticals lnc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, The Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Ipsen S.A., Kyowa Kirin Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Mylan N.V., Regeneron Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Hospira Inc., Apotex Inc.
Adverse Effects Pose A Challenge To Tnf Alpha Inhibitor Market Growth
The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitor market. The multiple adverse effects of TNF alpha inhibition identified by clinical trials and post-marketing surveillance include injection site reactions, neutropenia, infusion reactions, and infections. According to the U.S. According to the Food and Drug Administration (FDA), TNA alpha inhibitors can cause serious infections in people with weaker immune systems or low resistance levels. The infections can be bacterial, mycobacterial, fungal, or viral, leading to various diseases such as tuberculosis, histoplasmosis, candidiasis, blastomycosis, and hepatitis B. These side effects force patients to prefer alternatives such as non-TNF biologics, which hampers the growth of the TNF alpha inhibitors market.
Research And Development Efforts Drive Innovations In The Tnf Alpha Inhibitors Market
The companies in the market are focusing on research and development for TNF alpha inhibitors market. The focus on research and development activities allows companies in the market to evaluate and accept high-quality research proposals from all over the world and provide biologically and clinically superior performance with a more comfortable patient experience and faster recovery times. For example, in February 2022, MyMD Pharmaceuticals, Inc., a US based clinical stage pharmaceutical company committed to extending healthy lifespan, announced Phase 1 clinical trial data demonstrating MYMD-1’s reduction of tumor necrosis factor-alpha (TNF-a), the molecules that are the root cause of aging, in the blood of healthy human subjects. MYMD-1 has shown effectiveness in pre-clinical studies in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-a), a driver of chronic inflammation.
Major Companies Opting For Strategic Collaborations To Broaden Tnf Alpha Inhibitor Market And Product Portfolios
Major companies operating in the TNF alpha inhibitor market are integrating their efforts in adopting strategic collaborations to expand their product portfolios and make TNF-blockers available to patients. Product distribution, in this scenario, refers to the process of making products, such as TNF-alpha inhibitors, available for purchase by dispersing them through the market. For instance, in June 2023, Mark Cuban Cost Plus Drug Company, a US-based pharmaceutical company, partnered with Coherus BioSciences Inc., a US-based biopharmaceutical company, to offer Mark Cuban Cost Plus Drug Company customers YUSIMRY (adalimumab-aqvh), a biosimilar of HUMIRA (adalimumab injection). YUSIMRY is a tumor necrosis factor (TNF) blocker approved to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa, as well as to lessen the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis. This arrangement is a component of Coherus' biosimilar strategy, which aims to take advantage of its superior manufacturing and supply chain management capabilities to produce safe and efficient biosimilars with guaranteed, dependable supply.
Amgen Acquires Horizon Therapeutics To Bolster Tnf Inhibitor Portfolio
In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics PLC for $27.8 billion. This acquisition complies with Amgen's fundamental business goal of providing patients with critical diseases with cutting-edge medications that significantly improve their lives. Horizon Therapeutics PLC is a US-based biopharmaceutical company involved in the development and marketing of TNF inhibitors for the treatment of RA (rheumatoid arthritis).
North America was the largest region in the TNF alpha inhibitors market in 2023. The regions covered in the tnf alpha inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the TNF alpha inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The TNF alpha inhibitors market consists of sales of infliximab, adalimumab, etanercept, golimumab, and certolizumab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The TNF alpha inhibitors market research report is one of a series of new reports from The Business Research Company that provides TNF alpha inhibitors market statistics, including global market size, regional shares, competitors with a TNF alpha inhibitors market share, detailed TNF alpha inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the TNF alpha inhibitors industry. This TNF alpha inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.